In this podcast and accompanying article, we interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the most efficient ways to optimize fed-batch cell culture production for CHO-based antibodies. This included a discussion of media vs. feed strategies, incorporating critical quality attributes, evaluating the impact of optimizing on downstream processing and more.

In this podcast and accompanying article, we interviewed Dr. Mats Lundgren, PhD Customer Applications Director, Life Sciences, GE Healthcare, Sweden about developing platform processes for viral vector manufacturing and Mats describes a recently developed platform process for adenovirus production.

Panel discussion that I moderated at this year’s Cell and Gene Therapy Bioprocessing and Commercialization Conference. The discussion covers the latest in gene therapy manufacturing strategies, analytical analysis, cost of goods and key regulatory considerations.

Panel discussion on key considerations for moving cell therapies from lab to commercial manufacturing, including the benefits of manufacturing in a closed system. We also discussed what were some of the key hurdles and possible solutions associated with transitioning to clinical and commercial cell therapy manufacturing.

In this podcast, we interviewed Avril Vermunt, bioprocess hardware specialist at GE healthcare about transferring a process from a non-GMP to a GMP environment, particularly how resource-intensive it is for process development and manufacturing groups. Avril has several years of experience working in the technology transfer group at a large pharmaceutical company. We discussed with her best practices and how being proactive and one step ahead can make the process more seamless.

View show notes at downstreamcolumn.com/podcast/facilitate-transfer-from-non-gmp-to-gmp-manufacturing/

In this podcast, we interviewed Dr. Yuyi Shen about the benefits of modeling disruptive technologies to improve downstream bioprocessing and evaluating the financial impact of implementing these technologies.

View show notes at downstreamcolumn.com/podcast/modeling-downstream-disruptive-technologies-to-improve-downstream-bioprocessing/

Dr. Ross Macdonald, CEO Cynata Therapeutics, talks about the use of mesenchymal stem cells for Cell Therapy applications and key criteria for successful mesenchymal stem cell manufacturing.

Ricardo Baptista, Lead Process Development Scientist, Cell and Gene Therapy Catapult, UK talks about his impressions on current bioprocessing technologies for stem Cell Therapy manufacturing and possible future innovations.

Dr. Robert Preti talks about the past, present, and future of global Cell Therapy manufacturing. We also discussed major industry milestones, manufacturing challenges, and opportunities for further improvements.

In this podcast, we interviewed Dr. Peter Levison, Senior Marketing Director – Downstream Processing, Pall Life Sciences about the evolution and benefits of continuous biomanufacturing, what implementation looks like today and what still needs to be realized for full industry adoption.

View show notes at downstreamcolumn.com/podcast/continuous-biomanufacturing-implementation-now-and-in-the-future/